R-T:R(Stivarga 40mg) for the first period and T(Regorafenib 40mg) for the second period

2 trials

Sponsors

Beijing shijitan hospital affiliated to capital medical university

Conditions

mCRC/GIST/HCCmetastatic colorectal cancer (mCRC), gastrointestinal stromal tumor (GIST), hepatocellular carcinoma (HCC)

Phase 1

Randomized, open, single-dose, two-period, cross-over bioequivalence study of regorafenib in healthy volunteers under fasting condition

Active, not recruitingChiCTR2400092562

Beijing shijitan hospital affiliated to capital medical universitymCRC/GIST/HCC

Start: 2021-09-22Updated: 2024-12-02

Randomized, open, single-dose, two-period, cross-over bioequivalence study of regorafenib in healthy volunteers under low-fat fed condition

Active, not recruitingChiCTR2400093332

Beijing shijitan hospital affiliated to capital medical universitymetastatic colorectal cancer (mCRC), gastrointestinal stromal tumor (GIST), hepatocellular carcinoma (HCC)

Start: 2021-06-16Updated: 2024-12-09